HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies
Status:
Recruiting
Trial end date:
2023-02-20
Target enrollment:
Participant gender:
Summary
HS-201 is Verteporfin-tethered HSP90 inhibitor for clinical imaging of selective tumor
binding. HS-201 consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP
binding domain connected by a linker to a photosensitizing agent (verteporfin) that can be
used for imaging. HS-201 can freely enter tumor cells to selectively bind Hsp90. Due to the
the verteporfin, HS-201 accumulation in the malignant cells allows for specific visualization
of tumors within the body and verteporfin may allow for photodynamic therapy of tumors.